S

Southeastern Retina Associates | Knoxville, TN

Research site

(Unclaimed)

Location

140 Capital Drive, Suite 2A, Knoxville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

Lampalizumab

bevacizumab

Serine

Fenofibrate

Triamcinolone Acetonide

Pegaptanib

ranibizumab

Avastin®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 12 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Biological: 4D-150 IVT (3E10 vg/eye)

Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting

Diabetic Retinopathy

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Intravitreal Ranibizumab 0.5 mg Injection

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (BURGUNDY)

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Active, not recruiting

Macular Degeneration

Drug: Ranibizumab

Drug: Zifibancimig